Showing 1 - 9 results of 9 for search 'Yuh‐Pyng Sher', query time: 0.04s Refine Results
  1. 1
    An Overview of ADAM9: Structure, Activation, and Regulation in Human Diseases

    An Overview of ADAM9: Structure, Activation, and Regulation in Human Diseases by Cheng-Wei Chou, Yu-Kai Huang, Ting-Ting Kuo, Jing-Pei Liu, Yuh-Pyng Sher

    Published 2020-10-01
    Get full text
    Article
  2. 2
    Immunological evaluation of a novel HLA-A2 restricted phosphopeptide of tumor associated Antigen, TRAP1, on cancer therapy

    Immunological evaluation of a novel HLA-A2 restricted phosphopeptide of tumor associated Antigen, TRAP1, on cancer therapy by Min-Han Lin, Kuan-Yin Shen, Bing-Sin Liu, I-Hua Chen, Yuh-Pyng Sher, Guan-Chin Tseng, Shih-Jen Liu, Wang-Chou Sung

    Published 2019-04-01
    Get full text
    Article
  3. 3
    ADAM9 up-regulates N-cadherin via miR-218 suppression in lung adenocarcinoma cells.

    ADAM9 up-regulates N-cadherin via miR-218 suppression in lung adenocarcinoma cells. by Yuh-Pyng Sher, Li-Ju Wang, Li-Ling Chuang, Mong-Hsun Tsai, Ting-Ting Kuo, Cheng-Chung Huang, Eric Y Chuang, Liang-Chuan Lai

    Published 2014-01-01
    Get full text
    Article
  4. 4
    A Polypeptide of Tumor-Associated Antigen L6 with Intrinsic Adjuvant Activity Enhances Antitumor Immunity

    A Polypeptide of Tumor-Associated Antigen L6 with Intrinsic Adjuvant Activity Enhances Antitumor Immunity by Yuh-Pyng Sher, Kit Man Chai, Wen-Ching Chen, Kuan-Yin Shen, I-Hua Chen, Ming-Hui Lee, Fang-Feng Chiu, Shih-Jen Liu

    Published 2020-10-01
    Get full text
    Article
  5. 5
    A disintegrin and metalloproteinase domain 9 facilitates SARS-CoV-2 entry into cells with low ACE2 expression

    A disintegrin and metalloproteinase domain 9 facilitates SARS-CoV-2 entry into cells with low ACE2 expression by Ivonne Melano, Wei-Chung Cheng, Li-Lan Kuo, Yuag-Meng Liu, Yu Chi Chou, Mien-Chie Hung, Michael M. C. Lai, Yuh-Pyng Sher, Wen-Chi Su

    Published 2023-10-01
    Get full text
    Article
  6. 6
    EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis

    EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis by Chi-Chen Fan, Sheng-Ta Tsai, Chen-Yuan Lin, Ling-Chu Chang, Juan-Cheng Yang, Guan‐Yu Chen, Yuh-Pyng Sher, Shao-Chun Wang, Michael Hsiao, Wei‐Chao Chang

    Published 2020-07-01
    Get full text
    Article
  7. 7
    Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment

    Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment by Sze‐Ching Wong, Chun‐Chieh Yeh, Xun‐Yu Zhang, Chih‐Ying Hsieh, Chia‐Chien Lo, Ting‐Ting Kuo, Ching‐Chan Lin, Chih‐Hua Chao, Jing‐Pei Liu, Ling‐Chu Chang, Lu‐Hai Wang, Yuh‐Pyng Sher

    Published 2023-08-01
    Get full text
    Article
  8. 8
    Systematic identification of clinically relevant miRNAs for potential miRNA-based therapy in lung adenocarcinoma

    Systematic identification of clinically relevant miRNAs for potential miRNA-based therapy in lung adenocarcinoma by Shu-Hsuan Liu, Kai-Wen Hsu, Yo-Liang Lai, Yu-Feng Lin, Fang-Hsin Chen, Pei-Hwa Peng, Li-Jie Lin, Heng-Hsiung Wu, Chia-Yang Li, Shu-Chi Wang, Min-Zu Wu, Yuh-Pyng Sher, Wei-Chung Cheng

    Published 2021-09-01
    Get full text
    Article
  9. 9
    Using bioinformatics approaches to identify survival-related oncomiRs as potential targets of miRNA-based treatments for lung adenocarcinoma

    Using bioinformatics approaches to identify survival-related oncomiRs as potential targets of miRNA-based treatments for lung adenocarcinoma by Chia-Hsin Liu, Shu-Hsuan Liu, Yo-Liang Lai, Yi-Chun Cho, Fang-Hsin Chen, Li-Jie Lin, Pei-Hua Peng, Chia-Yang Li, Shu-Chi Wang, Ji-Lin Chen, Heng-Hsiung Wu, Min-Zu Wu, Yuh-Pyng Sher, Wei-Chung Cheng, Kai-Wen Hsu

    Published 2022-01-01
    Get full text
    Article

Search Tools: